Facts Game da Tivicay (dolutegravir)

Ciwon kwayar cutar kwayar cutar ta HIV ya tashi zuwa Amurka

Tivicay (dolutegravir) wani mai amfani ne wanda ke hana maganin cutar HIV. Shi ne karo na biyu a cikin ƙungiyar masu haɗaka masu haɗaka don yarda da Cibiyar Abinci da Druggun Amurka (FDA).

An ba Tivicay izinin lasisi na FDA a ranar 12 ga Agusta, 2013, don amfani da tsofaffi da yara masu shekaru 12 ko tsufa wadanda suke auna akalla 88 lbs (40kg) kuma ba a taɓa magance su ba tare da hadewa.

(Tivicay ba a amince da ita ba ga yara a karkashin 12 kodayake gwaje-gwaje na asibiti na Phase III suna aiki don tantance lafiyarsa da inganci a cikin wannan shekara.)

Tivicay kuma wani bangaren ne na yau da kullum, maganin hade-hade mai lamba , Triumeq , wanda ya hada da kwayoyi abacavir da lamivudine. FDA ta amince da Triumeq a ranar 22 ga Agusta, 2014.

Binciken Bincike na Clinical Research

Binciken na VIKING-3 ya nuna cewa Tivicay yana da tasiri a cikin kashi 63% na marasa lafiya marasa lafiya da juriya da nau'o'i na kwayoyin cutar HIV, ciki har da masu hadewa mai suna Isentress (ratelgravir) da kuma elvitegravir (a cikin kwayar kwayar cutar guda daya, .

Binciken SINGLE ya nuna cewa marasa lafiya a Tivicay suna da mummunar tasiri na katsewa saboda mummunan magani da yafi Atripla (tenofovir + emtricitabine + efavirenz). Bayan makonni 48, kashi 2 cikin dari na batutuwa akan tsarin Tivicay sun dakatar da magani tare da 10% na wadanda ke karbar Atripla.

Yankewa

Bugu da ƙari, ga yara da suke aiki da Sustiva (efavirenz), Aptivus (tipranavir) + Norvir (ritonavir), Lexiva (fosamprenavir) + Norvir (ritonavir), ko rifampin, kashi na Tivicay na 50mg, sau biyu a kullum.

Ba'a sani ba tukuna idan Tivicay yana da tasiri a cikin yara tare da haɗakar haɗin gwiwar mai hanawa.

Drug Administration

Tivicay za a iya ɗauka tare da ko ba tare da abinci ba, kuma a kowane lokaci na rana.

Hanyoyin Kasuwanci

Abubuwan da aka fi sani dasu (abin da ke faruwa a cikin 2% ko žananan lokuta) sune:

Drug Interactions ko Incompatibility

Tikosyn (dofetilide), wanda aka yi amfani da shi wajen maganin arrhythmia (ƙwaƙwalwar ajiyar zuciya), an ƙin yarda don amfani da Tivicay.

Don kaucewa yin hulɗar miyagun ƙwayoyi da miyagun ƙwayoyi, ba da shawara ga likitan ka kake shan kowane magunguna ko magunguna masu biyowa:

Abubuwa

> Sources:

Ƙungiyar Ma'aikatar Medicine ta Amurka. "TIVICAY (dolutegravir sodium) kwamfutar hannu, mai rufi na fim." Bethesda, Maryland; sabunta watan Agusta 2013.

ViiV Lafiya. "Kamfanin kiwon lafiya na ViiV ya sami amincewar FDA ga Triumeq." London, Ingila; latsa wallafawa 22 Agusta 2014.

Walmsley S .; Antela, A .; Hoto, N .; et al. "Dolutegravir (DTG; S / GSK1349572) + abacavir / lamivudine sau ɗaya yau da kullum a kan mahimmanci na statoci zuwa tenofovir / emtricitabine / efavirenz: sakamako na 48-makon - SINGLE (ING114467)." 52nd taro na rashin jin daɗin ciki game da Antimicrobial Agents da Chemotherapy. San Francisco; Satumba 9-12, 2012; Abubuwan H-556b.

Nichols, G .; Grossberg, R .; Lazzarin, A; et al. "Ayyukan Antiviral na Dolutegravir a cikin Suhimmanci Tare da Rashin Gidawar Tsarin Maƙalar Bincike: Week 24 Farkon 3 Sakamako Daga VIKING-3." 11th Congress Congress on Drug Far in HIV Infection (HIV11). Glasgow, Scotland; Nuwamba 11-15, 2012; Abubuwan O232.